Amicus Therapeutics (NASDAQ:FOLD) CEO Sells 14,587 Shares

Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Bradley Campbell sold 14,587 shares of the company’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $10.01, for a total transaction of $146,015.87. Following the completion of the transaction, the chief executive officer owned 1,137,282 shares in the company, valued at approximately $11,384,192.82. This represents a 1.27% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Amicus Therapeutics Stock Performance

FOLD stock traded up $0.05 on Wednesday, hitting $9.78. The company had a trading volume of 2,641,459 shares, compared to its average volume of 4,228,768. The stock has a market cap of $3.02 billion, a price-to-earnings ratio of -244.44 and a beta of 0.46. The company has a current ratio of 2.99, a quick ratio of 2.09 and a debt-to-equity ratio of 1.70. The stock’s 50-day simple moving average is $8.88 and its 200 day simple moving average is $7.47. Amicus Therapeutics, Inc. has a 12-month low of $5.51 and a 12-month high of $10.57.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.05. Amicus Therapeutics had a positive return on equity of 6.95% and a negative net margin of 2.35%.The business had revenue of $169.06 million during the quarter, compared to analyst estimates of $165.24 million. During the same quarter in the previous year, the company posted $0.10 earnings per share. Amicus Therapeutics’s revenue for the quarter was up 19.5% on a year-over-year basis. As a group, equities research analysts expect that Amicus Therapeutics, Inc. will post 0.15 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on FOLD. Wall Street Zen raised shares of Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. The Goldman Sachs Group boosted their price target on Amicus Therapeutics from $9.00 to $11.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 5th. Needham & Company LLC upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a report on Thursday, September 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Amicus Therapeutics in a report on Monday. Finally, Zacks Research raised Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, October 6th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $16.57.

Institutional Investors Weigh In On Amicus Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Osaic Holdings Inc. grew its position in shares of Amicus Therapeutics by 450.1% during the second quarter. Osaic Holdings Inc. now owns 4,104 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 3,358 shares during the last quarter. EverSource Wealth Advisors LLC raised its stake in Amicus Therapeutics by 472.6% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 4,455 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 3,677 shares in the last quarter. Strs Ohio acquired a new position in Amicus Therapeutics during the 1st quarter worth $30,000. ANTIPODES PARTNERS Ltd bought a new position in shares of Amicus Therapeutics in the third quarter worth $31,000. Finally, Allworth Financial LP lifted its holdings in Amicus Therapeutics by 36.3% in the third quarter. Allworth Financial LP now owns 4,678 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 1,246 shares during the period.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.